Which one of the following would you first need to determine is uniquely expressed in a tumor cell in order to change a "blocking" monoclonal antibody like Herceptin or Cetuximab into a chemotherapeutic "smart bomb" to target just that cell?
| A. An overexpressed tumor-specific transcription factor (e.g., c-myc). |
| B.
A tumor-specific protein kinase (e.g., BRAFV600E).
|
| C. A tumor-specific absence of a tumor suppressor like NF1 or p53. |
| D.
A tumor-specific G protein (e.g., RasD).
|
| E. A tumor-specific integral plasma membrane protein. |